These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Agonist or levodopa for Parkinson disease?: ultimately, it doesn't matter; neither is good enough. Weiner WJ; Reich SG Neurology; 2008 Aug; 71(7):470-1. PubMed ID: 18695156 [No Abstract] [Full Text] [Related]
6. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Fahn S; Poewe W Mov Disord; 2015 Jan; 30(1):1-3. PubMed ID: 25488146 [No Abstract] [Full Text] [Related]
7. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Schapira AH Mov Disord; 2008; 23 Suppl 3():S515-20. PubMed ID: 18781678 [TBL] [Abstract][Full Text] [Related]
8. 50 years of levodopa. Hornykiewicz O Mov Disord; 2015 Jun; 30(7):1008. PubMed ID: 25999218 [No Abstract] [Full Text] [Related]
16. Welcome news about levodopa, but uncertainty remains. Fahn S Ann Neurol; 1998 May; 43(5):551-4. PubMed ID: 9585348 [No Abstract] [Full Text] [Related]
17. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Kordower JH Mov Disord; 2017 Apr; 32(4):483-484. PubMed ID: 28425143 [No Abstract] [Full Text] [Related]
18. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease]. Dubois B; Montastruc JL Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616 [No Abstract] [Full Text] [Related]
19. Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa. Burdick DJ; Griffith A; Agarwal P Mov Disord; 2013 Mar; 28(3):295. PubMed ID: 23526432 [No Abstract] [Full Text] [Related]
20. [Epidemiological assessment of levodopa consumption]. de Pedro-Cuesta J; Cuadrado JI Rev Neurol; 2000 Dec 1-15; 31(11):1028-30. PubMed ID: 11190867 [No Abstract] [Full Text] [Related] [Next] [New Search]